title: Clinical significance of cytomegalovirus viremia in bone marrow transplantation.
abstract: Cytomegalovirus (CMV) viremia was systematically studied in 56 patients having undergone bone marrow transplantation for leukemia or aplastic anemia. Of the patients who survived at least three months, 57% had CMV viremia with a frequency peak between the 7th and the 9th weeks. We describe possible clinical signs associated with viremia, particularly late peripheral and/or central thrombocytopenia. The occurrence of viremia was studied according to the specific preexisting immune status of recipients and donors; granulocyte transfusions and graft-versus-host disease. The relationship between these parameters and viremia provides a basis for the analysis of prophylactic treatments of CMV infection.
authors.forename: E
authors.initials: E
authors.lastname: Vilmer
authors.forename: M C
authors.initials: MC
authors.lastname: Mazeron
authors.forename: C
authors.initials: C
authors.lastname: Rabian
authors.forename: O
authors.initials: O
authors.lastname: Azogui
authors.forename: A
authors.initials: A
authors.lastname: Devergie
authors.forename: Y
authors.initials: Y
authors.lastname: Perol
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002472:Cell Transformation, Viral; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000097:blood / Q000209:etiology* / Q000276:immunology; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D014184:Transplantation, Homologous / Q000009:adverse effects; D014766:Viremia / Q000097:blood / Q000209:etiology* / Q000276:immunology